EXHIBIT 10.3

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE
CONFIDENTIAL PORTIONS HAVE BEEN REDACTED AND ARE DENOTED BY A TRIPLE ASTERISK
(***). THE CONFIDENTIAL PORTIONS HAVE BEEN SEPARATELY FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION.

                  APPENDIX 11 - TRADEMARK ASSIGNMENT AGREEMENT
                              TRADEMARK ASSIGNMENT

            THIS TRADEMARK ASSIGNMENT is made on this 17th day of March 2006, by
and between Ipsen Ltd., a company organized and existing under the laws of
England, with registered offices located at 190 Bath Road, Slough, Berkshire SL1
3XE, United Kingdom ("Assignor"), and Aesthetica Ltd., a Bermuda corporation, a
wholly owned subsidiary of Medicis Pharmaceutical Corporation, a Delaware
corporation, located at 8125 North Hayden Road, Scottsdale, Arizona 85258,
United States of America ("Assignee").

            WHEREAS, Assignor owns all right, title, and interest in and to the
trademark RELOXIN throughout the world, including all translations and
localizations of the word RELOXIN and including those registrations and
applications for registration listed on the attached Schedule "A", and all
common law rights therein, together with all goodwill associated with said
trademarks and with the portion of the business to which the marks pertain as
required by 15 U.S.C. 1060 (collectively, the "Trademarks"); and

            WHEREAS, in connection with that certain Development and
Distribution Agreement of even date (the "DDA"), and in consideration of the
payments from Assignee to Assignor thereunder, Assignor has agreed to assign,
and Assignee has agreed to acquire, all of Assignor's right, title and interest
in and to the Trademarks, together with all rights, demands, claims, actions, or
causes of action of Assignor for misappropriation, infringement or dilution,
against third parties relating thereto;

            NOW, THEREFORE, Effective as of the Effective Date (as defined in
the DDA) for $*** and other good and valuable consideration, the receipt and
sufficiency of which the Parties hereby acknowledge., Assignor does hereby
assign, sell, transfer and convey to Assignee, the trademark RELOXIN throughout
the world, including those registrations and applications for registration
listed on the attached Schedule "A", in all classes of use (including those
indicated on Schedule "A"), and all common law rights therein, together with all
goodwill associated and with the portion of the business to which the marks
pertain as required by 15 U.S.C. 1060 with said Trademarks.

            Assignor undertakes and agrees to execute, at the expense of the
Assignee, such further assurances as may reasonably be required in order to
permit the Assignee (or its successors and assigns) to hold and enjoy the
Trademarks assigned hereunder and to obtain recording of this Trademark
Assignment. The Parties agree to reiterate their consent to this Agreement by
confirmatory acts or contracts which might be required after the date of
execution of this Agreement to complete the necessary formalities for its
execution, particularly, the filing of the assignments of the Trade Marks and
the Trade Mark Applications at national and international trade mark agencies.



            This Assignment shall be governed by New York substantive law and
may be executed in duplicate originals and may be executed in two counterparts,
and all of such counterparts taken together shall be deemed to constitute one
and the same agreement.



            IN WITNESS WHEREOF, Assignor and Assignee have caused this Trademark
Assignment to be executed by duly authorized officers as of the day and year
first above written.

                          IPSEN LTD.

                          By: /s/ Alistair Stokes
                              -------------------------

                          Name: Alistair Stokes

                          Title: Chief Executive Officer

                          AESTHETICA LTD.

                          By: /s/ Mark A. Prygocki, Sr.
                              -------------------------

                          Name: Mark A. Prygocki, Sr.

                          Title: President



                                  SCHEDULE "A"

                                  TRADE-MARKS



                                             Serial/Application    Registration
 Trademark    Country          Status               Number             Number       Class
----------    -------------    ----------    ------------------    -------------    -----
                                                                     
RELOXIN       United States    Registered       78267163            2920018         5
RELOXIN       Australia        Registered       1031310             1031310         5
RELOXIN       Hong Kong        Registered       300325449           300325449       5
RELOXIN       Japan            Registered       2004-107417         4883778         5
RELOXIN       New Zealand      Registered       721857              721857          5
RELOXIN       Singapore        Registered       T0420477B           T0420477B       5
RELOXIN       Argentina        Pending          2,556,368                           5
RELOXIN       Brazil           Pending          826989420                           5
RELOXIN       Canada           Pending          1225120                             NA
RELOXIN       China            Pending          4404754                             5
RELOXIN       European         Pending          3550878                             3,5,44
              Community
RELOXIN       Mexico           Pending          689658                              5
RELOXIN       Russian          Pending          2004727366                          5
              Federation
RELOXIN       South Korea      Pending          40-2004-53609                       5
RELOXIN       Taiwan           Pending          093054832                           5